Last reviewed · How we verify
IMN
IMN is an immunomodulatory agent designed to enhance immune responses against cancer cells.
IMN is an immunomodulatory agent designed to enhance immune responses against cancer cells. Used for Cancer immunotherapy (specific indication under investigation in phase 3).
At a glance
| Generic name | IMN |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
IMN works by activating and enhancing the body's innate and adaptive immune systems to recognize and eliminate malignant cells. The drug is being developed as an immunotherapeutic approach, potentially through toll-like receptor activation or similar innate immune pathways. It is being investigated in combination with other immunotherapies in phase 3 clinical trials.
Approved indications
- Cancer immunotherapy (specific indication under investigation in phase 3)
Common side effects
Key clinical trials
- Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases (NA)
- A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria (PHASE2)
- A Randomized Trial to Assess Patient Quality of Life and Function After Alternative Surgeries for Pathologic Fractures of the Femur (NA)
- Clinical Study of Anti-CD19/BCMA Universal Chimeric Antigen Receptor T Cells (UCAR-T) in the Treatment of Refractory Idiopathic Membranous Nephropathy (IMN) (EARLY_PHASE1)
- Rivaroxaban in Idiopathic Membranous Nephropathy (PHASE4)
- Intramedullary Calcium Sulfate Antibiotic Depot (PHASE3)
- Different Immunosuppressive Treatment in iMN (PHASE3)
- Rituximab Combined With Cyclosporine Versus Rituximab Alone in the Treatment of iMN (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMN CI brief — competitive landscape report
- IMN updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI